

Placebo Publications October 2017

1. Blasini, M., Corsi, N., Klinger, R., & Colloca, L. (2017). Nocebo and pain: An overview of the psychoneurobiological mechanisms. *Pain Rep*, 2(2). doi:10.1097/PR9.0000000000000585
<https://www.ncbi.nlm.nih.gov/pubmed/28971165>
2. Butler, J., & Anker, S. D. (2017). The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure? *Circulation*, 136(16), 1459-1461. doi:10.1161/CIRCULATIONAHA.117.029284
<https://www.ncbi.nlm.nih.gov/pubmed/29038205>
3. Caplandies, F., Colagiuri, B., Helfer, S. G., & Geers, A. L. (2017). Effect type but not attribute framing alters nocebo headaches in an experimental paradigm. *Psychology of Consciousness: Theory, Research, and Practice*, 4, 259-273. <http://psycnet.apa.org/record/2017-34737-001>
4. Colloca, L. (2017). Nocebo effects can make you feel pain. *Science*, 358(6359), 44. doi:10.1126/science.aap8488
<https://www.ncbi.nlm.nih.gov/pubmed/28983038>
5. Colloca, L. (2017). Sham opioids relieve multidimensional aspects of chronic back pain. *Pain*, 158(10), 1849-1850. doi: 10.1097/j.pain.0000000000000996
<https://www.ncbi.nlm.nih.gov/pubmed/28930921>
6. Cunningham, N. A., Abhyankar, P., Cowie, J., Galinsky, J., & Methven, K. (2017). Regenerative medicine: Stroke survivor and carer views and motivations towards a proposed stem cell clinical trial using placebo neurosurgery. *Health Expect.* doi:10.1111/hex.12632
<https://www.ncbi.nlm.nih.gov/pubmed/29024214>
7. Faria, V., Gingnell, M., Hoppe, J. M., Hjorth, O., Alaie, I., Frick, A., Hultberg, S., Wahlstedt, K., Engman, J., Mansson, K.N.T., Carlbring, P., Andersson, G., Reis, M., Larsson, E.M., Fredrikson, M., Furmark, T. (2017). Do You Believe It? Verbal Suggestions Influence the Clinical and Neural Effects of Escitalopram in Social Anxiety Disorder: A Randomized Trial. *EBioMedicine*. doi:10.1016/j.ebiom.2017.09.031
<https://www.ncbi.nlm.nih.gov/pubmed/29033138>

8. Forsberg, J. T., Gjerstad, J., Flaten, M. A., & Aslaksen, P. M. (2017). The influence of Catechol-O-Methyltransferase Val158Met on fear of pain and placebo analgesia. *Pain*. doi:10.1097/j.pain.0000000000001081
<https://www.ncbi.nlm.nih.gov/pubmed/28968343>
9. Kirsch, I. (2017). Response Expectancy and the Response to Antidepressant Medication. *EBioMedicine*. doi:10.1016/j.ebiom.2017.09.038
<https://www.ncbi.nlm.nih.gov/pubmed/29037605>
10. Klinger, R., Blasini, M., Schmitz, J., & Colloca, L. (2017). Nocebo effects in clinical studies: hints for pain therapy. *Pain Rep*, 2(2). doi:10.1097/PR9.0000000000000586
<https://www.ncbi.nlm.nih.gov/pubmed/29034363>
11. Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R.C., Kossowsky, J. (2017). Efficacy and Safety of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, and Placebo for Common Psychiatric Disorders Among Children and Adolescents: A Systematic Review and Meta-analysis. *JAMA Psychiatry*, 74(10), 1011-1020. doi:10.1001/jamapsychiatry.2017.2432
<https://www.ncbi.nlm.nih.gov/pubmed/28854296>
12. Ozawa, C., Roberts, R., Yoshida, K., Suzuki, T., Lebowitz, B., Reeves, S. Howard, R., Abe, T., Mimura, M., Uchida, H. (2017). Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease: Analysis of the CATIE-AD Data. *J Clin Psychiatry*. doi:10.4088/JCP.17m11461
<https://www.ncbi.nlm.nih.gov/pubmed/29045769>
13. Rezk, M. F., & Pieper, B. (2017). Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect. *Rheumatol Ther*. doi:10.1007/s40744-017-0085-z
<https://www.ncbi.nlm.nih.gov/pubmed/29032452>
14. Rughinis, C., Ciocanel, A., & Vasile, S. (2017). Homeopathy as Boundary Object and Distributed Therapeutic Agency. A Discussion on the Homeopathic Placebo Response. *Am J Ther*. doi:10.1097/MJT.0000000000000607
<https://www.ncbi.nlm.nih.gov/pubmed/28984633>
15. Skyt, I., Moslemi, K., Bastrup, C., Grosen, K., Benedetti, F., Petersen, G. L., Price, D.D., Hall, K.T., Kaptchuk, T.J., Svensson, P., Jensen, T.S., Vase, L. (2017). Dopaminergic tone does not influence pain levels during placebo interventions in patients with chronic neuropathic pain. *Pain*. doi:10.1097/j.pain.0000000000001089
<https://www.ncbi.nlm.nih.gov/pubmed/29068872>

16. Tetreault, P., & Apkarian, A. V. (2017). [Predicting placebo response with functional magnetic resonance imaging]. *Med Sci (Paris)*, 33(6-7), 599-602.
doi:10.1051/medsci/20173306014
<https://www.ncbi.nlm.nih.gov/pubmed/28990559>
17. Thibault, R. T., & Raz, A. (2017). The psychology of neurofeedback: Clinical intervention even if applied placebo. *Am Psychol*, 72(7), 679-688.
doi:10.1037/amp0000118
<https://www.ncbi.nlm.nih.gov/pubmed/29016171>
18. Tinnermann, A., Geuter, S., Sprenger, C., Finsterbusch, J., & Buchel, C. (2017). Interactions between brain and spinal cord mediate value effects in nocebo hyperalgesia. *Science*, 358(6359), 105-108. doi:10.1126/science.aan1221
<https://www.ncbi.nlm.nih.gov/pubmed/28983051>
19. Tweehuysen, L., van den Bemt, B. J. F., van Ingen, I. L., de Jong, A. J. L., van der Laan, W. H., van den Hoogen, F. H. J., & den Broeder, A. A. (2017). Subjective Complaints as Main Reason for Biosimilar Discontinuation after Open Label Transitioning from Originator to Biosimilar Infliximab. *Arthritis Rheumatol*. doi:10.1002/art.40324
<https://www.ncbi.nlm.nih.gov/pubmed/29045077>
20. van Meeuwis, S. H., Middendorp, H. V., Veldhuijzen, D. S., van Laarhoven, A. I. M., de Houwer, J., Lavrijsen, A. P. M., & Evers, A. W. M. (2017). Placebo Effects of Open-label Verbal Suggestions on Itch. *Acta Derm Venereol*. doi:10.2340/00015555-2823
<https://www.ncbi.nlm.nih.gov/pubmed/29057429>